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AbstrACt
background Malignant pleural mesothelioma (MPM) 
is a highly lethal malignancy in need for new treatment 
options. Although immunotherapies have been shown to 
boost a tumor- specific immune response, not all patients 
respond and prognostic biomarkers are scarce. In this 
study, we determined the peripheral blood T cell receptor 
β (TCRβ) chain repertoire of nine MPM patients before 
and 5 weeks after the start of dendritic cell (DC)- based 
immunotherapy.
Materials and methods We separately profiled PD1+ and 
PD1−CD4+ and CD8+ T cells, as well as Tregs and analyzed 
70 000 TCRβ sequences per patient.
results Strikingly, limited TCRβ repertoire diversity and 
high average clone sizes in total CD3+ T cells before the 
start of immunotherapy were associated with a better 
clinical response. To explore the differences in TCRβ 
repertoire prior- DC- therapy and post- DC- therapy, for 
each patient the TCRβ clones present in the total CD3+ T 
cell fractions were classified into five categories, based 
on therapy- associated frequency changes: expanding, 
decreasing, stable, newly appearing and disappearing 
clones. Subsequently, the presence of these five groups 
of clones was analyzed in the individual sorted T cell 
fractions. DC- therapy primarily induced TCRβ repertoire 
changes in the PD1+CD4+ and PD1+CD8+ T cell fractions. 
In particular, in the PD1+CD8+ T cell subpopulation we 
found high frequencies of expanding, decreasing and 
newly appearing clones. Conversion from a PD1− to a PD1+ 
phenotype was significantly more frequent in CD8+ T cells 
than in CD4+ T cells. Hereby, the number of expanding 
PD1+CD8+ T cell clones—and not expanding PD1+CD4+ T 
cell clones following immunotherapy positively correlated 
with overall survival, progression- free survival and 
reduction of tumor volume.
Conclusion We conclude that the clinical response to 
DC- mediated immunotherapy is dependent on both the 
pre- existing TCRβ repertoire of total CD3+ T cells and 
on therapy- induced changes, in particular expanding 
PD1+CD8+ T cell clones. Therefore, TCRβ repertoire 
profiling in sorted T cell subsets could serve as predictive 
biomarker for the selection of MPM patients that benefit 
from immunotherapy.
trial registration number NCT02395679.
IntroduCtIon
Malignant pleural mesothelioma (MPM) 
is a highly lethal malignancy that is often 
caused by asbestos fiber inhalation. Current 
treatment consists of a combination chemo-
therapy with antifolate and platinum, with 
an overall survival (OS) of 13.3 months and 
therefore novel effective treatment options 
are urgently needed.1
Recent breakthroughs that use cancer 
immunotherapy to enhance immune activa-
tion have revolutionized cancer treatment. 
These include inhibition of immune check-
point molecules such as PD1/PD- L1 and 
CTLA-4.2 However, MPM treatment with 
checkpoint inhibitors was found to be non- 
effective3 or only effective in a subpopulation 
of patients,4 5 likely due to low numbers of 
tumor- infiltrating lymphocytes (TILs)6 7 and 
a highly immunosuppressive tumor micro- 
environment.1 8
Compared with healthy individuals, in MPM 
patients circulating dendritic cells (DCs) are 
reduced in numbers and antigen- processing 
capacity, which is thought to contribute to the 
low numbers of TILs.9 Previously, we devel-
oped a DC- mediated immunotherapy for 
MPM with the aim to increase the number 
of TILs and tumor- directed T cells.10 Patients 
received multiple vaccinations with autolo-
gous DCs loaded with autologous tumor cell 
lysate. This strategy was safe and feasible and 
showed signs of clinical activity in patients. 
However, the limited availability of tumor 
material precluded treatment in many MPM 
patients. Therefore, vaccination with DCs 
loaded with allogeneic tumor lysate derived 
from five in vitro cultured clinical- grade 
human MPM cell lines was developed and 
proven safe and feasible in a phase I clinical 
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trial.11 Hereby, MPM patients were vaccinated three times 
with DCs once every 2 weeks and received booster vacci-
nations at three and 6 months after start of treatment. 
As part of the dose escalation study, each cohort of three 
patients received 10, 25 or 50 million DCs per vaccina-
tion. Objective radiographical responses were obtained, 
and one patient had a ~70% tumor reduction at 6 weeks 
after the first DC vaccination.11 Multicolor flow cytometry 
revealed that DC vaccination induced an increase in the 
number of circulating CD4+ T cells, CD8+ T cells and B 
cells.12 Furthermore, the frequency of HLA- DR, PD1 and 
inducible T- cell costimulator (ICOS)- expressing CD4+ T 
cells and LAG3- expressing CD8+ T cells increased after DC 
vaccination. Notably, the highest frequency of HLA- DR 
and ICOS- expressing CD4+ T cells was found in the best 
responding patient. No major treatment- associated T cell 
receptor (TCR) repertoire shifts were detected by anal-
ysis of TCRβ-chain complementarity- determining region 
3 (CDR3) length.12
Recent TCR sequencing studies indicated that TCRβ 
clone frequency and diversity are affected by immuno-
therapies, such as checkpoint inhibitors in pancreatic 
ductal carcinoma,13 lung cancer,14 15 and melanoma.16 17 
Hereby, TCRβ repertoire changes, including expansion 
or contraction of T cell clones, correlated with clinical 
response.14 18 Likewise, DC- therapy changed TCRβ clone 
frequency and diversity in glioma,19 melanoma20 and pros-
tate cancer,21 although correlations with clinical response 
were not reported.
In this study, we performed quantitative next genera-
tion sequencing- based human TCRβ repertoire profiling 
of peripheral blood of MPM patients obtained prior- DC 
and post- DC vaccination. To gain insight into the DC 
immunotherapy- induced TCRβ repertoire changes in 
PD1+ and PD1−CD4+ and CD8+ T cells, as well as Tregs, 
we separately analyzed these five T cell subpopulations. 
We observed that TCRβ repertoire changes significantly 
correlated with patient survival, indicating the potential 
of TCRβ profiling as a biomarker of clinical response to 
DC- based immunotherapy.
MAterIAls And Methods
Study design of the DC- based immunotherapy, FACS- 
sorting of T cell subsets, analysis of TCRβ repertoire and 
statistical evaluation are detailed in online supplementary 
materials and methods file.
results
dC-therapy induces tCrβ repertoire changes specifically in 
Pd1+Cd8+ t cells
To identify immunotherapy- induced TCRβ repertoire 
changes, we profiled fractions of total CD3+ T cells, PD1− 
and PD1+CD4+ T cells, PD1− and PD1+CD8+ T cells and 
Tregs from peripheral blood of nine MPM patients pre- 
DC- therapy and 5 weeks post- DC- therapy (see online 
supplementary figure S1 for gating strategy). The 
numbers of retrieved TCRβ sequences varied across the 
T cell fractions (see online supplementary figure S2). To 
normalize the reads per T cell fraction, we used 25 000 
quality- filtered, randomly selected sequences per sample 
for the total CD3+ T cell fractions and 2000 sequences for 
the individual T cell subpopulations.
The PD1− and PD1+CD8+ T cell fractions showed the 
largest degree of clonal expansion, given their highest 
average clone size, both pre- therapy and post- therapy 
(figure 1A). The PD1+CD8+ T cell fractions showed the 
highest numbers of highly expanded clones (HECs; 
clones with a frequency ≥0.5%) (figure 1B). The HECs 
accounted for 46.2% (±12.8%) and 49.7% (±9.2%) of the 
total repertoire in PD1− and PD1+CD8+ T cells, respec-
tively, and was in the range of 2.7%–16.2% for the CD4+ T 
cell and Treg fractions (figure 1C).
Importantly, DC- therapy mainly induced changes in 
the PD1+CD8+ T cell population, as specifically in this 
fraction—and not in any of the other subpopulations—
the average TCRβ clone size tended to be increased. 
Additionally, the numbers of retrieved HECs significantly 
decreased, and the impact of the first dominant clone 
increased after DC- therapy (figure 1A–D). We saw this 
DC therapy- induced increase in the impact of dominant 
clones also when we analyzed the top five or 10 HECs 
(data not shown). This indicates that the most dominant 
clones increased in impact at the cost of the less domi-
nant clones, apparently without affecting the cumulative 
impact of the HECs on the total repertoire.
high average tCrβ clone sizes prior to dC-therapy correlate 
with favorable clinical responses
When we investigated the total CD3+ T cell fractions in 
more detail, we found that DC- therapy had no detectable 
effect on the impacts of the clonal sizes, Vβ usage, Vβ-Jβ 
recombination frequencies, mean TCRβ CDR3 length or 
charge (see online supplementary figure S3A–E). Inter-
estingly, the values for the average TCRβ clone size in 
the total CD3+ T cell fractions prior to DC- therapy were 
positively correlated with both OS (p=0.0186; r2=0.57) 
and progression free survival (PFS) (p=0.0227; r2=0.52) 
(figure 2A,B). Such a positive correlation was not 
observed after DC- therapy (see online supplementary 
figure S4A,B). We also did not find correlations between 
OS or PFS and TCRβ clone size in the CD4+, CD8+ T cells 
or Treg subpopulations (data not shown).
dC-therapy selectively induces expanding and newly 
appearing Pd1+Cd4+ and Pd1+Cd8+ t cell clones
Next, we linked the TCRβ sequences present in the total 
CD3+ T cell fraction to those in the sorted T cell subpop-
ulations, using their unique CDR3 sequences. When we 
focused on the 25 most dominant TCRβ clones present 
in the CD3+ T cell population, we observed that for all 
patients the majority of these clones could be retrieved 
in multiple T cell subpopulations, particularly in both 
the PD1+ and in the PD1−CD8+ T cell fraction. The TCRβ 
clone distribution over the T cell subpopulations was 
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Figure 1 Characteristics of the TCRβ repertoire before and after DC- therapy. Analysis of 25 000 TCRβ sequence reads (for 
the total CD3+ T cell fraction) and 2000 TCRβ sequence reads (for all other T cell fractions indicated). (A) Average clone size, 
shown as the average numbers of reads per clone; (B) numbers of highly expanded TCRβ clones (HECs) retrieved; (C) impact 
of all HECs on the total repertoire; (D) impact of the first dominant clone on the total repertoire. Each symbol represents values 
for a sorted T cell fraction, either pre- DC- therapy (closed circle) or post- DC- therapy (open circle). Paired samples are shown 
connected by black lines. Significance after paired t- test is shown in each graph, with *p<0.05. P values were corrected for 
multiple testing, using the Benjamini and Hochberg False Discovery Rate. DC, dendritic cell; TCRβ, T cell receptor β.
Figure 2 TCRβ clone sizes in total CD3+ T cells prior to DC- therapy correlate with favorable clinical responses. (A, B) Scatter 
plots of the number of reads per CD3+ T cell clone pre- DC- therapy (x- axis) versus the overall survival in months (y- axis in A) and 
the progression free survival in months (y- axis in B). Linear regression curve fitting, p values and r2 are shown for each graph. 
DC, dendritic cell.
similar in pre- DC- therapy and post- DC- therapy samples 
(figure 3A). For all patients only a small proportion of 
the clones were retrieved in the CD3+ T cells only.
To explore the differences in TCRβ repertoire prior- 
DC- therapy and post- DC- therapy, for each patient the 
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Figure 3 Clonal changes in the TCRβ repertoire after DC- therapy. (A) Composition of the 25 most dominant TCRβ HECs in 
the CD3+ T cell repertoire. Data for all individuals are plotted as mean values and SD using black bars for the repertoire pre- DC- 
therapy and white bars for the repertoire post- DC- therapy. (B) Representative plot showing the degree of overlap between the 
repertoire pre- DC- therapy (x- axis) and the repertoire post- DC- therapy (y- axis) in a total CD3+ T cell sample. Each dot represents 
one TCRβ clone and its clonal frequency in the total repertoire is shown as the percentage of the total number of 25 000 
reads in the sample. Clones are color coded, as indicated, according to their differential expression defined in Materials and 
Methods. Gray dots with a frequency <0.01% were classified as background. (C, D, E) Cumulative frequencies of expanding 
(C), decreasing (D) and stable (E) clones present in the indicated T cell subpopulations pre- DC- therapy (closed circle) and post- 
DC- therapy (open circle). Paired samples are shown connected by black lines. Significance of paired t- test is shown in each 
graph; **p<0.01 and ***p<0.001. (F, G) Cumulative frequencies of newly appearing (F) and disappearing (G) CD3+ T cell clones 
after treatment. (H, I) Percentage of the newly appearing (H) and disappearing (I) PD1+ clones that are found as PD1− before 
treatment, both in CD4+ and CD8+ T cells. Significance of t- test is shown in each graph; *p<0.05, **p<0.01 and ***p<0.001. P 
values were corrected for multiple testing, using the Benjamini and Hochberg False Discovery Rate. DC, dendritic cell; TCRβ, T 
cell receptor β chain.
TCRβ clones present in the total CD3+ T cell fractions 
were classified into five groups, based on their pres-
ence and fold change in clonal frequency: expanding, 
decreasing, stable, newly appearing and disappearing 
clones (figure 3B). Subsequently, the presence of these 
five groups of clones was analyzed in the individual sorted 
T cell fractions.
The TCRβ clones in the total CD3+ T cell populations 
that expanded on DC- therapy, were also expanded in 
the PD1− and PD1+CD8+ T cell fractions (figure 3C). 
Decreasing TCRβ clones were mainly retrieved in the 
PD1+CD4+ and PD1+CD8+ T cell fractions (figure 3D). 
Stable TCRβ clones in the total CD3+ T cell populations 
had the largest cumulative frequency in the PD1− and 
PD1+CD8+ T cell fractions (figure 3E), which was likely 
a reflection of the high average clone sizes and high 
numbers of HECs within CD8+ T cells (figure 1A,B).
TCRβ clones that were newly induced were particularly 
retrieved in the PD1+CD4+ and PD1+CD8+ T cell fractions 
(figure 3F). Disappearing TCRβ clones were present in 
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Figure 4 Correlations of TCRβ chain repertoires changes after dendritic cell- therapy with clinical outcome. (A, B, C) Number of 
expanding PD1+CD8+ T cell clones after treatment versus overall survival in months (A), progression free survival in months (B) 
and the change in tumor volume at 6 weeks after treatment versus baseline (in C). Linear regression curve fitting, p values and r2 
are shown for each graph.
all T cell fractions, but remarkably low in the PD1−CD8+ T 
cell fractions (figure 3G).
To identify therapy- induced PD1 expression, we investi-
gated whether new PD1+ clones within the CD4+ or CD8+ 
T fractions could be retrieved in corresponding PD1− T 
cell fractions prior DC- therapy. Only small proportions 
of the new TCRβ clones in the post- therapy CD4+ and 
CD8+PD1+ T cell subpopulations (~2.7% and ~10%, 
respectively) were retrieved in the corresponding PD1− T 
cell fractions (figure 3H). PD1 expression was apparently 
lost in ~4.3% of CD4+ T cells and ~8.8% of CD8+ T cells 
(figure 3I).
Taken together, we observed that DC- therapy mainly 
induced TCRβ changes, involving expanding, newly 
appearing and decreasing clones, in the PD1+CD4+ and 
PD1+CD8+ T cell subpopulations. Conversion from a 
PD1− to a PD1+ phenotype or vice versa was significantly 
more frequent in CD8+ than in CD4+ T cells.
Numbers of expanding PD1+CD8+ T cells clones 
correlate with clinical response to DC- therapy
Because DC- therapy mainly affected the TCRβ reper-
toires of PD1+CD4+, PD1+CD8+ and Treg cell fractions, we 
investigated the characteristics of these subpopulations in 
more detail. Only minor changes were found in Vβ gene 
usage, CDR3 charge and length between the five catego-
ries of TCRβ clones in these T cell subpopulations (see 
online supplementary figure S5). When we compared the 
amino acid sequences deduced from the RNA sequences 
of the new and expanding TCRβ clones across the nine 
patients, we identified no shared expanded clones and 13 
shared new clones (see online supplementary table S1).
The numbers of expanding clones did not differ signifi-
cantly between PD1+CD4+ T cells, PD1+CD8+ T cells 
and Tregs (see online supplementary figure S6A). The 
numbers of decreased and stable PD1+CD8+ clones were 
significantly higher than decreased and stable PD1+CD4+ 
or Treg clones (see online supplementary figure S6B,C). 
The numbers of new and disappearing PD1+CD8+ T 
clones were significantly lower than new and disappearing 
PD1+CD4+ T cells or Tregs (see online supplementary 
figure S6D,E). This is in line with the higher average 
number of reads per clone and the high impact of HECs 
in PD1+CD8+ T cells (figure 1A).
Next, we assessed whether these TCRβ repertoire 
features were associated with clinical response. Strikingly, 
the number of expanding PD1+CD8+ T cell clones signifi-
cantly correlated with both OS (p=0.0441; r2=0.4616), 
PFS (p=0.0041; r2=0.7152) and radiographical change in 
tumor volume, measured at ~6 weeks after DC- therapy 
(p=0.0351; r2=0.4924) (figure 4A–C). In contrast, these 
correlations were not observed with the number of 
expanding PD1+CD4+ T cell clones (see online supple-
mentary figure S7) or Tregs, nor in any of the other TCRβ 
clone categories (data not shown).
In conclusion, the number of expanding PD1+CD8+—
but not PD1+CD4+—T cell clones in MPM patients 
induced by DC- therapy significantly correlated with 
clinical response. This indicates that clinical efficacy of 
DC- therapy depends on a pre- existing PD1+CD8+ T cell 
response.
dIsCussIon
Immunotherapeutic strategies have been shown to acti-
vate the immune system and to boost tumor- specific 
immune responses,2 but not all patients show clinical 
improvement. Sensitive methods to monitor the immune 
response after treatment and biomarkers predicting clin-
ical benefit are scarce. To the best of our knowledge, 
we are the first to investigate TCRβ repertoire changes 
induced by DC- mediated immunotherapy in different T 
cell subpopulations. We studied peripheral blood samples 
from nine MPM patients who received autologous DCs 
loaded with allogeneic tumor lysate derived from cultured 
human MPM cell lines. This treatment strategy showed 
feasibility and promising clinical activity and immunolog-
ical responses.11 12
For each patient we analyzed 70 000 TCRβ sequences 
to characterize the TCRβ repertoire composition before 
and 5 weeks after the start of DC- therapy. We analyzed 
total CD3+ T cells and five fluorescence- activated 
cell sorting (FACS)- sorted subpopulations: PD1− and 
PD1+CD4+ and CD8+ T cells and CD25+CD127low Tregs. 
This analysis revealed that limited TCRβ repertoire diver-
sity in total CD3+ T cells (inferred from a high number 
of reads per clone) before the start of immunotherapy 
was associated with a better clinical response. DC- based 
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immunotherapy induced TCRβ repertoire changes 
particularly in the PD1+CD4+ and PD1+CD8+ T cell 
subpopulations. These included expansion, contraction, 
appearance and disappearance of TCRβ clones, as well 
as apparent conversions from PD1− into PD1+ and vice 
versa. Immunotherapy- induced repertoire changes were 
more extensive in PD1+CD8+ T cells, given the significant 
increase in average clone size (figure 1A), changes in 
the numbers and impact of HECs (figure 1B,C) and the 
high levels of dynamics of PD1 expression (figure 3G,H). 
Importantly, the number of expanding PD1+CD8+—but 
not PD1+CD4+—T cell clones following immunotherapy 
positively correlated with OS, PFS and reduction of 
tumor volume. From these findings, we conclude that 
TCRβ repertoire profiling in both total CD3+ T cells and 
sorted T cell subsets could serve as predictive biomarker 
for clinical response in MPM patients to immunotherapy. 
Further studies including larger patient groups should 
show which of the two parameters correlates best with 
clinical outcome. We previously reported that all patients 
revealed strong responses to DCs loaded with tumor 
lysate and keyhole limpet hemocyanin 48 hours after 
DTH skin testing, providing evidence that DC- based 
immunotherapy is capable of inducting immunological 
response to tumor cells. This may also be supported by 
our current finding of 13 newly appearing clones that are 
shared between patients.
Our observation that a high average baseline TCRβ 
clone size is beneficial for a clinical response in MPM is 
in line with similar findings following anti- CTLA-4 treat-
ment in pancreatic ductal adenocarcinoma patients13 and 
following anti- PD1 treatment in melanoma patients.22–24 
Thus, the presence of circulating expanded T cell clones 
is generally beneficial for the clinical response to immu-
notherapy, irrespective of the treatment approach. 
Future studies should show whether these clones reflect 
a pre- existing tumor- specific T cell response. By contrast, 
in metastatic breast cancer patients low TCR diversity in 
conjunction with lymphopenia predicts poor OS, indi-
cating that TCR diversity might reflect a measure of 
immunological fitness.25
DC- based immunotherapy in MPM patients induced 
selective expansion of TCRβ clones and a diversification 
of the repertoire driven by newly appearing clones, paral-
leling published observations in melanoma patients.20 
Likewise, the number of expanding clones was increased 
in responding NSCLC patients treated with radiation 
therapy and CTLA-4 blockade,14 although in contrast to 
our study the T cell subset in which this expansion was 
most prominent was not determined. It is interesting that 
the frequency of expanding PD1+CD8+ T cells was highest 
in the MPM patient with a substantial tumor volume 
reduction of ~70%. Also, when patients with pancreatic 
ductal adenocarcinoma were treated with anti- CTLA-4 
antibodies, it was observed that patients with >100 
expanded clones survived nearly three times longer than 
patients with lower numbers of expanding clones.13
Thus, TCR diversity have previously been correlated 
with clinical outcome for checkpoint inhibitor immu-
notherapy.13 14 22 24 26 In this context, it is important to 
note that clinical studies using checkpoint inhibitors of 
CTLA-4 and PD1 were unsuccessful in mesothelioma, 
according the recently presented PembROlizuMab 
Immunotherapy Versus Standard Chemotherapy for 
Advanced prE- treated Malignant Pleural Mesothelioma 
(PROMISE- meso) trial and the DETERMINE study, 
wherein the effectivity of Tremelimumab (anti- CTLA-4) 
as second or third- line treatment was investigated in 
relapsed malignant mesothelioma patients.3 Therefore, it 
is important that a limited TCRβ repertoire diversity in 
total CD3+ T cells correlates with clinical benefit not only 
in checkpoint- inhibitor treatment, but also in DC- medi-
ated immunotherapy.
Our TCRβ repertoire analysis showed that DC- therapy 
mainly shapes the PD1+CD8+ T cell population and that 
the clinical response to therapy is particularly linked to 
CD8+ T cell function. Therefore, it seems valuable to 
profile TCR repertoire changes in specific T cell subsets, 
certainly because correlations between TCR repertoire 
changes and clinical outcome may be obscured by differ-
ential effects of immunotherapy on individual T cell 
subpopulations. We chose to separately analyze the TCR 
repertoire in PD1− and PD1+ T cells, because this coinhib-
itory marker is not only a hallmark of exhausted T cells, 
but it is also transiently expressed on activated T cells and 
identifies the CD8+ tumor- reactive repertoire.27 Given the 
limited number of patients analyzed in this study, our 
findings need to be validated in a larger and indepen-
dent DC- therapy cohort. Validation studies in a larger 
cohorts, will indicate which predictive TCR parameter 
correlates best with clinical outcome, and should indicate 
additional associations between demographic data and 
clinical response.
In summary, with this study we showed that DC- therapy 
in MPM patients specifically induced TCRβ repertoire 
changes in PD1+CD8+ T cells that correlate with clinical 
outcome. Additionally, high average TCRβ clone sizes 
in total CD3+ T cells before the start of immunotherapy 
were associated with a better clinical response. Therefore, 
TCRβ repertoire profiling in both total CD3+ T cells as 
sorted T cell subsets could serve as a biomarker to monitor 
or to predict the responses of patients to treatment.
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